| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/27/2007 | CA2370244C Piperidine derivatives |
| 03/27/2007 | CA2326611C Substituted heterocyclic derivatives |
| 03/27/2007 | CA2312744C Apparatus and method for diluting nasal sprays containing addictive compounds |
| 03/27/2007 | CA2297149C 13-deoxyanthracycline derivatives for treating cancer |
| 03/27/2007 | CA2278842C Use of peroxygen compounds in the control of hairy wart disease |
| 03/27/2007 | CA2251820C Substituted benzylamines and their use for the treatment of depression |
| 03/27/2007 | CA2247520C Pharmaceutical composition with base of rhein or diacerhein with improved biological availability |
| 03/27/2007 | CA2242750C Antibodies with reduced net positive charge |
| 03/27/2007 | CA2219651C Antifungal composition |
| 03/27/2007 | CA2209669C Composition and methods for transdermal delivery of acid-labile drugs |
| 03/27/2007 | CA2208149C Sustained release caffeine formulation |
| 03/27/2007 | CA2208018C Sulfonamides |
| 03/27/2007 | CA2200582C Dna encoding human papillomavirus type 6a |
| 03/27/2007 | CA2200084C Use of aromatic halides for treating mammalian cell proliferation |
| 03/27/2007 | CA2180841C 1-aminoindan derivatives and compositions thereof |
| 03/27/2007 | CA2179733C Anticonvulsant pseudofructopyranose sulfamates |
| 03/27/2007 | CA2168879C Skin patches and methods for providing testosterone |
| 03/27/2007 | CA2019580C Novel methods of treatment using ranolazine and related piperazine derivatives |
| 03/23/2007 | WO2008096189A2 Piperidine and piperazine derivatives |
| 03/23/2007 | CA2631096A1 Piperidine and piperazine derivatives |
| 03/22/2007 | WO2007033366A2 Biphenyl-pyrazolecarboxamide compounds |
| 03/22/2007 | WO2007033350A1 Dipeptidyl peptidase inhibitors for treating diabetes |
| 03/22/2007 | WO2007033307A2 Inhibition of intermediate-conductance calcium activated potassium channels in the treatment and/or prevention of atherosclerosis |
| 03/22/2007 | WO2007033292A2 Combination therapy for controlled carbohydrate digestion |
| 03/22/2007 | WO2007033281A2 Ion exchange resin treated to control swelling |
| 03/22/2007 | WO2007033269A1 Composition comprising a dendrimer and the use thereof for binding phosphate |
| 03/22/2007 | WO2007033266A2 Dipeptidyl peptidase inhibitors for treating diabetis |
| 03/22/2007 | WO2007033265A1 Dipeptidyl peptidase inhibitors for treating diabetis |
| 03/22/2007 | WO2007033232A1 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
| 03/22/2007 | WO2007033231A2 Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives |
| 03/22/2007 | WO2007033214A2 Esters of compounds in the leptomycin family |
| 03/22/2007 | WO2007033208A2 Use of indirubin and its derivatives in the treatments of hiv infection and heart failure |
| 03/22/2007 | WO2007033196A1 Met kinase inhibitors |
| 03/22/2007 | WO2007033192A1 Salicylate and gentisate salts of a piperazine compound |
| 03/22/2007 | WO2007033191A1 Glucuronate salt of a piperazine compound |
| 03/22/2007 | WO2007033175A1 Indolobenzazepine hcv ns5b inhibitors |
| 03/22/2007 | WO2007033137A1 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
| 03/22/2007 | WO2007033112A1 Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| 03/22/2007 | WO2007033082A2 Compositions comprising dimethyl sulfoxide (dmso) |
| 03/22/2007 | WO2007033080A2 Alzheimer's disease imaging agents |
| 03/22/2007 | WO2007033039A2 Proteasome inhibiting beta lactam compounds |
| 03/22/2007 | WO2007033032A1 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| 03/22/2007 | WO2007033002A1 Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| 03/22/2007 | WO2007032997A1 Ophthalmic formulation containing loteprednol etabonate for treatment of dry eye |
| 03/22/2007 | WO2007032962A2 Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| 03/22/2007 | WO2007032818A2 Compounds and compositions to control abnormal cell growth |
| 03/22/2007 | WO2007032808A1 Crystalline trihydrate of zoledronic acid |
| 03/22/2007 | WO2007032794A2 Inhibition of viral gene expression using small interfering rna |
| 03/22/2007 | WO2007032770A2 Serotonin and catecholamine segment optimization technology |
| 03/22/2007 | WO2007032720A1 Method and means of preventing and treating sleep disordered breathing |
| 03/22/2007 | WO2007032699A1 (+)-and-(-)-trans-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1h-pyrido[4,3-b] indole optical isomers |
| 03/22/2007 | WO2007032688A1 Anthelmintic formulations |
| 03/22/2007 | WO2007032643A1 A solubilized material comprising ubidecarenone, aqueous solution and process for preparation thereof |
| 03/22/2007 | WO2007032591A1 Composition comprising 1-furan-2-yl-3-pyridin-2-yl-pr0pen0ne having anti-angiogenic activity and cancer growth inhibitory activity |
| 03/22/2007 | WO2007032572A1 N-substituted-1h-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same |
| 03/22/2007 | WO2007032557A1 Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects |
| 03/22/2007 | WO2007032556A1 Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
| 03/22/2007 | WO2007032551A1 Hemodynamics improving agent |
| 03/22/2007 | WO2007032536A1 Histamine h3 agonist for use as therapeutic agent for lipid/glucose metabolic disorder |
| 03/22/2007 | WO2007032466A1 Heterocyclic compound, and production process and use thereof |
| 03/22/2007 | WO2007032445A1 Protein kinase inhibitors |
| 03/22/2007 | WO2007032371A1 Oxindole derivative as feeding control agent |
| 03/22/2007 | WO2007032362A1 Substituted cycloalkene derivative |
| 03/22/2007 | WO2007032340A1 COMPOSITION CONTAINING α-LIPOIC ACID |
| 03/22/2007 | WO2007032028A1 Thiazolinones and oxazolinones and their use as ptp1b inhibitors |
| 03/22/2007 | WO2007032023A2 A process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetic acid methyl ester or salts thereof having higher chiral purity and products thereof |
| 03/22/2007 | WO2007032021A2 Method and system for customization of multi-language conversions in mobile phones |
| 03/22/2007 | WO2007032016A1 An antimalarial baylis-hillman adducts and a process for the preparation thereof |
| 03/22/2007 | WO2007032012A2 Device for tire inflation |
| 03/22/2007 | WO2007032010A2 Use of tellurium compounds for protection from ultra-violet radiation |
| 03/22/2007 | WO2007032009A2 Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis |
| 03/22/2007 | WO2007032005A2 Novel amine-borane compounds and uses thereof |
| 03/22/2007 | WO2007031977A2 Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors |
| 03/22/2007 | WO2007031968A2 Porous coating loaded with a liquid or a solid substance |
| 03/22/2007 | WO2007031867A2 A hepatitis c virus non-stru tural ns3/4a fusion gene |
| 03/22/2007 | WO2007031860A1 Indane substituted benzimidazoles and their use as acid pump inhibitors |
| 03/22/2007 | WO2007031853A2 Therapeutic combination of hamlet and a hdac inhibitor to treat cancer |
| 03/22/2007 | WO2007031846A2 Pharmaceutical composition |
| 03/22/2007 | WO2007031845A2 Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation |
| 03/22/2007 | WO2007031838A1 Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| 03/22/2007 | WO2007031832A2 Use of bipyridine compound 'caerulomycin a' derivatives and analogs thereof as immunosuppressive agents |
| 03/22/2007 | WO2007031828A2 Therapeutic pyrrolidines |
| 03/22/2007 | WO2007031812A1 Chitosan-based particles |
| 03/22/2007 | WO2007031801A1 IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF |
| 03/22/2007 | WO2007031791A1 Biphenyl derivatives and their use in treating hepatitis c |
| 03/22/2007 | WO2007031747A1 Imdolizine derivatives as ligands of the crth2 receptor |
| 03/22/2007 | WO2007031745A1 Pyrimidine derivatives for the inhibition of igf-ir tyrosine kinase activity |
| 03/22/2007 | WO2007031739A1 Heterobicyclic compounds as glucokinase activators |
| 03/22/2007 | WO2007031737A1 4,4-dimethylpiperidine-2,6-dione derivatives for use in the treatment of hypertension |
| 03/22/2007 | WO2007031726A1 Purine derivatives having immuno-modulating properties |
| 03/22/2007 | WO2007031725A1 Food supplement |
| 03/22/2007 | WO2007031721A1 Midazole-4-carboxamide derivatives for use as cb modulators |
| 03/22/2007 | WO2007031720A1 1,2-diarylimidazoles for use as cbi modulators |
| 03/22/2007 | WO2007031632A1 Combination of bioavailable methionine with at least one essential oil |
| 03/22/2007 | WO2007031608A1 Collagen receptor i-domain binding modulators |
| 03/22/2007 | WO2007031558A1 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension |
| 03/22/2007 | WO2007031529A1 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity |
| 03/22/2007 | WO2007031501A2 Pyridylsulfonamidyl-pyrimidines for the prevention of blood vessel graft failure |
| 03/22/2007 | WO2007031428A1 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives |
| 03/22/2007 | WO2007031349A1 Use of c3-c10 17alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents. |